Christine S. Huang

Christine S. Huang

Auto-generated profile, based on publicly available information

Christine S. Huang

Department of Biological Sciences, Columbia University, New York, New York 10027, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Cell
Verified
Journal Article
Closed access
MWMatthew E. Welsch
Matthew E. Welsch
AKAnna Kaplan
Anna Kaplan
JCJennifer M. Chambers
Jennifer M. Chambers
MSMichael E. Stokes
Michael E. Stokes
PBPieter H. Bos
Pieter H. Bos
BSBrent R. Stockwell
Brent R. Stockwell

30 May 2006 in Journal of Cell Biology
Verified
Journal Article
Open access
JKJeffrey D. Kearns
Jeffrey D. Kearns
SBSoumen Basak
Soumen Basak
SWShannon L. Werner
Shannon L. Werner
CHChristine S. Huang
Christine S. Huang
AHAlexander Hoffmann
Alexander Hoffmann
NF-κB signaling is known to be critically regulated by the NF-κB–inducible inhibitor protein IκBα. The resulting negative feedback has been shown to produce a propensity for oscillations in NF-κB activity. We report integrated experimental and computational studies that demonstrate that another IκB isoform, IκBε, also provides negative feedback on NF-κB activity, but with distinct functional consequences. Upon stimulation, NF-κB–induced transcription of IκBε is delayed, relative to that of IκBα, rendering the two negative feedback loops to be in antiphase. As a result, IκBε has a role in dampening IκBα-mediated oscillations during long-lasting NF-κB activity. Furthermore, we demonstrate the requirement of both of these distinct negative feedback regulators for the termination of NF-κB activity and NF-κB–mediated gene expression in response to transient stimulation. Our findings extend the capabilities of a computational model of IκB–NF-κB signaling and reveal a novel regulatory module of two antiphase negative feedback loops that allows for the fine-tuning of the dynamics of a mammalian signaling pathway.

1 May 2018 in Molecular Cell
Verified
Journal Article
Closed access
ECEric Conway
Eric Conway
EJEmilia Jerman
Emilia Jerman
EHEvan Healy
Evan Healy
SIShinsuke Ito
Shinsuke Ito
DHDaniel Holoch
Daniel Holoch
ABAdrian P. Bracken
Adrian P. Bracken

19 August 2010 in Nature
Verified
Journal Article
Open access
PDF file
CHChristine S. Huang
Christine S. Huang
KSKianoush Sadre-Bazzaz
Kianoush Sadre-Bazzaz
YSYang Shen
Yang Shen
BDBinbin Deng
Binbin Deng
ZZZ. Hong Zhou
Z. Hong Zhou
LTLiang Tong
Liang Tong
The mitochondrial biotin-dependent enzyme propionyl-coenzyme A carboxylase (PCC) is essential for the catabolism of several amino acids, cholesterol and some fatty acids. The X-ray crystal and cryo-electron microscopy structures of the α6β6 dodecamer of PCC have now been determined. They reveal that the α-subunit contains the biotin carboxylase (BC) and biotin carboxyl carrier protein (BCCP) domains; the β-subunit is responsible for the carboxyltransferase activity. The BC domain and the carboxyltransferase domain are 55 ångströms apart, indicating that the BCCP domain must move a large distance during the catalytic cycle. Propionyl-coenzyme A carboxylase (PCC) is a biotin-dependent enzyme that is essential for the catabolism of several amino acids, cholesterol and some fatty acids. Here, the crystal structure of a bacterial PCC is presented, along with a cryo-electron microscopy reconstruction showing a similar structure for human PCC. The structural information establishes a molecular basis for understanding the known disease-causing mutations in PCC, and is relevant to the holoenzymes of other biotin-dependent carboxylases. Propionyl-coenzyme A carboxylase (PCC), a mitochondrial biotin-dependent enzyme, is essential for the catabolism of the amino acids Thr, Val, Ile and Met, cholesterol and fatty acids with an odd number of carbon atoms. Deficiencies in PCC activity in humans are linked to the disease propionic acidaemia, an autosomal recessive disorder that can be fatal in infants1,2,3,4. The holoenzyme of PCC is an α6β6 dodecamer, with a molecular mass of 750 kDa. The α-subunit contains the biotin carboxylase (BC) and biotin carboxyl carrier protein (BCCP) domains, whereas the β-subunit supplies the carboxyltransferase (CT) activity. Here we report the crystal structure at 3.2-Å resolution of a bacterial PCC α6β6 holoenzyme as well as cryo-electron microscopy (cryo-EM) reconstruction at 15-Å resolution demonstrating a similar structure for human PCC. The structure defines the overall architecture of PCC and reveals unexpectedly that the α-subunits are arranged as monomers in the holoenzyme, decorating a central β6 hexamer. A hitherto unrecognized domain in the α-subunit, formed by residues between the BC and BCCP domains, is crucial for interactions with the β-subunit. We have named it the BT domain. The structure reveals for the first time the relative positions of the BC and CT active sites in the holoenzyme. They are separated by approximately 55 Å, indicating that the entire BCCP domain must translocate during catalysis. The BCCP domain is located in the active site of the β-subunit in the current structure, providing insight for its involvement in the CT reaction. The structural information establishes a molecular basis for understanding the large collection of disease-causing mutations in PCC and is relevant for the holoenzymes of other biotin-dependent carboxylases, including 3-methylcrotonyl-CoA carboxylase (MCC)5,6,7 and eukaryotic acetyl-CoA carboxylase (ACC)8,9.

2 October 2019 in Nature
Verified
Journal Article
Closed access
PDF file
NONina Oberbeck
Nina Oberbeck
VPVictoria C. Pham
Victoria C. Pham
JWJoshua D. Webster
Joshua D. Webster
RRRohit Reja
Rohit Reja
CHChristine S. Huang
Christine S. Huang
VDVishva m Dixit
Vishva m Dixit

28 November 2019 in mAbs
Verified
Journal Article
Open access
CTCholpon Tilegenova
Cholpon Tilegenova
SISaeed Izadi
Saeed Izadi
JYJianping Yin
Jianping Yin
CHChristine S. Huang
Christine S. Huang
JWJiansheng Wu
Jiansheng Wu
PCPaul J. Carter
Paul J. Carter
Some antibodies exhibit elevated viscosity at high concentrations, making them poorly suited for therapeutic applications requiring administration by injection such as subcutaneous or ocular delivery. Here we studied an anti-IL-13/IL-17 bispecific IgG4 antibody, which has anomalously high viscosity compared to its parent monospecific antibodies. The viscosity of the bispecific IgG4 in solution was decreased by only ~30% in the presence of NaCl, suggesting electrostatic interactions are insufficient to fully explain the drivers of viscosity. Intriguingly, addition of arginine-HCl reduced the viscosity of the bispecific IgG4 by ~50% to its parent IgG level. These data suggest that beyond electrostatics, additional types of interactions such as cation-π and/or π-π may contribute to high viscosity more significantly than previously understood. Molecular dynamics simulations of antibody fragments in the mixed solution of free arginine and explicit water were conducted to identify hotspots involved in self-interactions. Exposed surface aromatic amino acids displayed an increased number of contacts with arginine. Mutagenesis of the majority of aromatic residues pinpointed by molecular dynamics simulations effectively decreased the solution’s viscosity when tested experimentally. This mutational method to reduce the viscosity of a bispecific antibody was extended to a monospecific anti-GCGR IgG1 antibody with elevated viscosity. In all cases, point mutants were readily identified that both reduced viscosity and retained antigen-binding affinity. These studies demonstrate a new approach to mitigate high viscosity of some antibodies by mutagenesis of surface-exposed aromatic residues on complementarity-determining regions that may facilitate some clinical applications.